glp 1 heart issues Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit Cardiologist: GLP1 Medications Reduce Heart

Fortin SM, Roitman MF

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) emerged as a promising class of drugs and have been shown to be effective as a key regulator in managing glucose metabolism-associated diseases such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), cardiovascular effects, nephrological complications, diabetes, non-alcoholic fatty liver (NAFLD), as well as to control obesity

Immediate sample processing (centrifugation, plasma separation, freezing at 80C) is essential to prevent ex vivo peptide degradation

Methods Computational analysissingle-cell sequencing datasets Table 2 summarizes the single-cell sequencing datasets used